Skip to main content Skip to main content
Go to homepage

MACI in patients with knee defects

Safety and efficacy of MACI in Patients with Chondral or Osteochondral Knee Defects (PEAK)


View complete study information here.

Interested in participating?
We are currently recruiting
Study Sponsor:

Vericel Corporation

Full IRB Study Title:
A prospective, open-label, randomized, concurrent active-controlled, longitudinal, multicenter, phase 3 clinical study of the safety and efficacy of MACI in patients aged 10 to 17 years with symptomatic chondral or osteochondral defects of the knee due to osteochondritis dissecans or acute trauma (PEAK Clinical Trial)
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Melanie Morscher, Study Coordinator, 330-543-8935

Lead Investigator
John Polousky, MD

Division Director, Orthopedic Sports Medicine

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.